---
title: "Fate Therapeutics reports lower Q4 collaboration revenue"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277055875.md"
datetime: "2026-02-26T14:09:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277055875.md)
  - [en](https://longbridge.com/en/news/277055875.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277055875.md)
---

# Fate Therapeutics reports lower Q4 collaboration revenue

)

Overview

-   Biopharmaceutical firm’s Q4 collaboration revenue fell yr/yr
-   Company reported Q4 net loss of $32.4 mln
-   Operating expenses decreased 30% in 2025 compared to 2024

Outlook

-   Company projects operating runway through year-end 2027 with $205 mln in cash
-   Fate Therapeutics to provide clinical updates in H2 2026
-   Company plans Phase 2 trial in lupus nephritis

Result Drivers

-   OUTPATIENT TREATMENT - FT819 off-the-shelf CAR T-cell therapy enabled outpatient treatment, expanding access and reducing hospital stays
-   CANCER THERAPY SUCCESS - FT836 showed significant tumor reduction in colorectal cancer without conditioning chemotherapy, highlighting early activity
-   COST REDUCTION - Company plans a 30% reduction in operating expenses in 2025 compared to 2024, supporting financial runway through 2027 Company press release:

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

### Q4 $1.37

Collabor mln

ation

Revenue

Q4 Net -$32.37

Income mln

Q4 Basic -$0.27

### EPS

### Q4 -$34.72

Income mln

from

Operatio

ns

### Q4 $36.09

Operatin mln

g

Expenses

Analyst Coverage

-   The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 6 “strong buy” or “buy”, 6 “hold” and no “sell” or “strong sell”
-   The average consensus recommendation for the biotechnology & medical research peer group is “buy”
-   Wall Street’s median 12-month price target for Fate Therapeutics Inc is $5.00, about 237.8% above its February 25 closing price of $1.48 For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

### Related Stocks

- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FATE.US](https://longbridge.com/en/quote/FATE.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [Fate Therapeutics Details Off-the-Shelf CAR T Progress in Lupus and Solid Tumors at Needham Conference](https://longbridge.com/en/news/282940584.md)
- [FDA Rejection Sparks Questions On Replimune Drug Approval Path](https://longbridge.com/en/news/282577359.md)
- [Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham](https://longbridge.com/en/news/282904330.md)
- [Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences](https://longbridge.com/en/news/282206169.md)
- [Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform](https://longbridge.com/en/news/282587297.md)